7 recruiting, 4 active not recruiting, 3 unknown, 1 completed. 8 Phase 2, 5 Phase 1, 3 Phase 3, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 6, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 5 | Active not recruiting 3, Recruiting 2 |
| Phase 3 | 3 | Recruiting 3 |
| Early Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Advanced Gastroesophageal Junction Adenocarcinoma: new trials by email Literature Review of Advanced Gastroesophageal Junction Adenocarcinoma trials Research Report on Advanced Gastroesophageal Junction Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma Intratumoral 2141-V11, Nivolumab, Fluoropyrimidine - Esophageal Cancer, Advanced Esophageal Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2026-09-04 | 2026-09-14 |
| Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer EB-DT-CAR-NK, Fludarabine, Cyclophosphamide - Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-04-24 |
| Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer Docetaxel, Oxaliplatin, Leucovorin - Gastric Cancer, Stomach Cancer | Phase 2 / Phase 3 | Recruiting | Ukrainian Society of Clinical Oncology | 150 | 2025-03-25 | 2025-05-06 |
| SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer SHR-A1811 & Apartinib - Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Yunpeng Liu | 28 | 2024-12-01 | 2024-10-30 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 224 | 2024-06-24 | 2026-10-23 |
| Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer. Peripheral blood, tougue coating, saliva, and feces - Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Unknown | Xiangdong Cheng | 150 | 2024-03-25 | 2024-10-15 | |
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment - Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 220 | 2023-08-23 | 2026-04-20 |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma Fluorouracil, Leucovorin Calcium, Oxaliplatin - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 382 | 2023-01-31 | 2026-10-02 |
| Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy Disitamab Vedotin - HER2, Advanced Gastric Cancer | Unknown | Shen Lin | 306 | 2023-01-01 | 2022-12-16 | |
| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Lenvatinib, Pembrolizumab - Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2022-02-14 | 2026-07-16 |
| Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery Carboplatin, Paclitaxel, Radiation Therapy - Advanced Esophageal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 1 | Active not recruiting | NRG Oncology | 16 | 2021-12-02 | 2026-10-01 |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 10 | 2021-08-13 | 2026-08-21 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin) - Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 20 | 2021-01-15 | 2021-08-12 |
| Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma Pembrolizumab - Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 9 | 2018-02-09 | 2023-11-18 |
Stomach Neoplasms (5) · Adenocarcinoma Of Esophagus (3) · Colorectal Neoplasms (3) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Lung Neoplasms (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1)
Neoplasms (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (6) · Neoplasms by Site (6) · Gastrointestinal Neoplasms (5) · Stomach Diseases (5) · Neoplasms by Histologic Type (4) · Colonic Diseases (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Rectal Diseases (3) · Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2)
Fluorouracil (4) · Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · Leucovorin (3) · Nivolumab (3) · dehydroftorafur (3) · Biopsy (2) · Irinotecan (2) · Oxaliplatin (2) · Paclitaxel (2) · Taxes (2) · pembrolizumab (2) · BAY 1895344 (1) · Carboplatin (1) · Cyclophosphamide (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Beijing Biotech (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · NRG Oncology (1) · Northwestern University (1) · Shen Lin (1) · Ukrainian Society of Clinical Oncology (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Xiangdong Cheng (1) · Yunpeng Liu (1)
United States (10) · China (5) · Lithuania (1) · Puerto Rico (1) · Ukraine (1)
Anwaar Saeed (1) · Devalingam Mahalingam (1) · Geoffrey Y Ku (1) · Jaffer A Ajani (1) · Kanwal P Raghav (1) · Lin Shen, MD (1) · Liza C Villaruz (1) · Mariela Blum (1) · Mykyta Pepenin, MD (1) · Roxana S. Dronca, MD (1) · Samuel Cytryn, MD (1)
PMID 36158692, PMID 39841295, PMID 40155326
P30CA060553 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186688 (1), UM1CA186690 (1)